Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...

Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, weighed down by pricing pressure in the competitive North American market, their biggest ...

DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Dr Reddy’s Laboratories ’ net profit is likely to remain little lower or almost flat at around ₹1360-65 crore in the third ...

Among patients with relapsed or refractory follicular lymphoma (FL), the treatment combination of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been found to ...

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American ...